BR112023003432A2 - Regime de tratamento para o tratamento de doenças autoimunes - Google Patents
Regime de tratamento para o tratamento de doenças autoimunesInfo
- Publication number
- BR112023003432A2 BR112023003432A2 BR112023003432A BR112023003432A BR112023003432A2 BR 112023003432 A2 BR112023003432 A2 BR 112023003432A2 BR 112023003432 A BR112023003432 A BR 112023003432A BR 112023003432 A BR112023003432 A BR 112023003432A BR 112023003432 A2 BR112023003432 A2 BR 112023003432A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- autoimmune diseases
- regime
- new
- treatment regimen
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 6
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 4
- 238000011269 treatment regimen Methods 0.000 abstract 3
- 208000015181 infectious disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Application Of Or Painting With Fluid Materials (AREA)
- Saccharide Compounds (AREA)
- Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
Abstract
REGIME DE TRATAMENTO PARA O TRATAMENTO DE DOENÇAS AUTOIMUNES. A presente invenção refere-se a um novo regime de tratamento para o tratamento de distúrbios autoimunes. O dito novo regime de tratamento fornece de preferência um tratamento eficaz de distúrbios autoimunes com um perfil de segurança vantajoso e/ou uma alta qualidade de vida para o paciente. De preferência, o dito novo regime de tratamento proporciona uma relação benefício-risco vantajosa para pacientes ameaçados pelo risco de infecções.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062706795P | 2020-09-10 | 2020-09-10 | |
| US202062706819P | 2020-09-11 | 2020-09-11 | |
| US202063198971P | 2020-11-25 | 2020-11-25 | |
| US202063199265P | 2020-12-16 | 2020-12-16 | |
| US202163149196P | 2021-02-12 | 2021-02-12 | |
| US202163175318P | 2021-04-15 | 2021-04-15 | |
| PCT/EP2021/074928 WO2022053608A1 (en) | 2020-09-10 | 2021-09-10 | Novel treatment regimen for the treatment of autoimmune disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023003432A2 true BR112023003432A2 (pt) | 2023-03-21 |
Family
ID=78080246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023003432A BR112023003432A2 (pt) | 2020-09-10 | 2021-09-10 | Regime de tratamento para o tratamento de doenças autoimunes |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4210710A1 (pt) |
| JP (1) | JP2023541877A (pt) |
| KR (1) | KR20230066402A (pt) |
| AU (1) | AU2021342333A1 (pt) |
| BR (1) | BR112023003432A2 (pt) |
| CA (1) | CA3194812A1 (pt) |
| IL (1) | IL301246A (pt) |
| MX (1) | MX2023002843A (pt) |
| WO (1) | WO2022053608A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023242285A1 (en) | 2022-06-15 | 2023-12-21 | Vektor Pharma Tf Gmbh | Sublingual formulation of anticancer compound for use in the treatment of autoimmune neurodegenerative diseases |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1269659A (en) | 1984-08-06 | 1990-05-29 | Brigham Young University | Method for the production of 2'-deoxyadenosine compounds |
| US5310732A (en) | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US5208327A (en) | 1991-12-18 | 1993-05-04 | Ortho Pharmaceutical Corporation | Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine |
| US5641757A (en) | 1994-12-21 | 1997-06-24 | Ortho Pharmaceutical Corporation | Stable 2-chloro-2'-deoxyadenosine formulations |
| EP0801571B1 (en) | 1994-12-22 | 2002-09-04 | Ortho Pharmaceutical Corporation | Soluble 2-chloro-2'-deoxyadenosine formulations |
| US6194395B1 (en) | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
| WO2000064918A1 (en) | 1999-04-28 | 2000-11-02 | Sterrenbeld Biotechnologie North America, Inc. | METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE |
| JP4757632B2 (ja) | 2002-09-25 | 2011-08-24 | ブリガム ヤング ユニバーシティー | ２’−デオキシグアノシンから２−クロロ−２’−デオキシアデノシンを調製する方法 |
| CA2520522C (en) | 2003-03-28 | 2012-05-29 | Ivax Corporation | Cladribine formulations for improved oral and transmucosal delivery |
| BR122018068797B1 (pt) | 2003-03-28 | 2021-04-27 | Ares Trading S.A. | Composições farmacêuticas de complexo de ciclodextrina-cladribina complexo, usos do referido complexo, bem como processos para a sua preparação |
| MXPA04010902A (es) * | 2004-11-03 | 2006-05-08 | Alvaro Raul Lara Rodriguez | Vacuna recombinante a partir de las proteinas ge, gi y gb del virus de varicela zoster como tratamiento y prevencion de esclerosis multiple. |
| WO2019101960A1 (en) * | 2017-11-24 | 2019-05-31 | Merck Patent Gmbh | Cladribine regimen for use intreating progressive forms of multiple sclerosis |
-
2021
- 2021-09-10 CA CA3194812A patent/CA3194812A1/en active Pending
- 2021-09-10 BR BR112023003432A patent/BR112023003432A2/pt unknown
- 2021-09-10 WO PCT/EP2021/074928 patent/WO2022053608A1/en active Application Filing
- 2021-09-10 MX MX2023002843A patent/MX2023002843A/es unknown
- 2021-09-10 JP JP2023515725A patent/JP2023541877A/ja active Pending
- 2021-09-10 KR KR1020237011881A patent/KR20230066402A/ko unknown
- 2021-09-10 AU AU2021342333A patent/AU2021342333A1/en active Pending
- 2021-09-10 IL IL301246A patent/IL301246A/en unknown
- 2021-09-10 EP EP21786771.2A patent/EP4210710A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4210710A1 (en) | 2023-07-19 |
| WO2022053608A1 (en) | 2022-03-17 |
| KR20230066402A (ko) | 2023-05-15 |
| MX2023002843A (es) | 2023-03-31 |
| IL301246A (en) | 2023-05-01 |
| JP2023541877A (ja) | 2023-10-04 |
| CA3194812A1 (en) | 2022-03-17 |
| AU2021342333A1 (en) | 2023-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018071347A2 (pt) | moduladores de nlrp3 | |
| BR112014027571A2 (pt) | métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas | |
| WO2015117010A3 (en) | Bag3 as a target for therapy of heart failure | |
| CO2020005351A2 (es) | Uso de inhibidores de p38 para reducir la expresión de dux4 | |
| BR112012008962A2 (pt) | derivados espiro-condensados de ciclohexano como inibidores de hsl úteis para o tratamento de diabetes | |
| BR112022009216A2 (pt) | Métodos e composições para tratar um distúrbio associado a angiotensinogênio (agt) | |
| BR112023003432A2 (pt) | Regime de tratamento para o tratamento de doenças autoimunes | |
| BR112021022789A2 (pt) | Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a | |
| BR112021017436A2 (pt) | Composições farmacêuticas para tratamento de doenças ou transtornos oculares | |
| BR112022007721A2 (pt) | Método para o tratamento da demência | |
| BR112019005995A2 (pt) | cristal não solvatado, método de preparação e aplicação do mesmo | |
| BR112017004729A2 (pt) | processo de tratamento de doenças causadas por metástase óssea, medicamentos para as mesmas e processo de previsão do resultado clínico de tratamento de doenças causadas por metástase óssea | |
| CY1124538T1 (el) | Χρηση prg4 για τη βελτιωση της δυναμικης οπτικης οξυτητας και εκτροπων υψηλοτερης ταξης | |
| CO2021016487A2 (es) | Vectores aav con el promotor de la proteína cero de mielina y usos de los mismos para el tratamiento de enfermedades asociadas a las células de schwann como la enfermedad de charcot-marie-tooth | |
| Esmail | The diagnosis and management of Parkinson’s disease | |
| BR112019009495A2 (pt) | métodos de tratamento de distúrbios inflamatórios com compostos de fc multivalentes | |
| BR112021018262A2 (pt) | Tratamento de doenças e distúrbios mitocondriais associados, incluindo sintomas dos mesmos usando pridopidina | |
| BR112023009172A2 (pt) | Métodos, sistemas e kits para tratamento de doenças inflamatórias direcionados à tl1a | |
| BR112017015613A2 (pt) | gel intestinal de levodopa e carbidopa e métodos de utilização | |
| BR112022020020A2 (pt) | Métodos de tratamento da doença do coronavírus 2019 | |
| BR112023020669A2 (pt) | Terapias de combinação para o tratamento de câncer | |
| CL2022000294A1 (es) | Composiciones biofarmacéuticas y procedimientos conexos. | |
| Sarısoy et al. | Defence styles and social adaptation during a depressive episode: bipolar depression vs. major depression | |
| BR112023019795A2 (pt) | Composições nasais compreendendo alcaftadina | |
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов |